CDKN1B and cancer: Early studies highlighted miR-221’s oncogenic role in cancer, where it was found to promote cell proliferation by targeting cyclin-dependent kinase inhibitors (cyclin dependent kinase inhibitor 1b (CDKN1B/p27), CDKN1C/p57) [5,14].